Loading...
Share this Job

DDI Scientist

 
Requistion ID:  1333
Location: 

Copenhagen, N/A, DK

Date: 
 

Scientist, In Vitro Drug-Drug Interaction Studies

We are looking for a Scientist for the Drug-Drug Interaction (DDI) group in the Department of Drug Metabolism. The Department of Drug Metabolism is part of the Drug ADME Research Division within Non-Clinical Safety Research. Non-Clinical Safety Research is responsible for the safety evaluation of novel drug candidates, small molecules as well as biologics, for the treatment of psychiatric and neurological disorders. The Department of Drug Metabolism is responsible for providing ADME and DDI data for worldwide registration of NCEs. Regarding DDI, we are responsible for evaluations of enzymes and transporters involved in drug disposition and assessment of inhibitory/induction potential of NCEs. We have at present 12 full-time positions, divided in two groups (DDI and Metabolism). The position is based in Lundbeck's Headquarter, Copenhagen. 

 

Your job and key responsibilities

You will be responsible for planning, executing and reporting of in vitro DDI studies supporting a very interesting pipeline. Thus, you will be performing studies such as enzyme reaction phenotyping, enzyme inhibition, enzyme induction, transporter inhibition and transporter substrate evaluations. As an important part of your work, you will be responsible for studies performed in our laboratories and in that role be sparring and guiding our technicians. Furthermore, you will work in close collaboration with Contract Research Organisations (CRO’s), who are performing studies on behalf of the DDI group.

As PBPK modelling and simulation is an integrated part of interpretation of the in vitro data generated in our studies, prior knowledge and hands on experience with model and simulation will be an advantage. Moreover, you will also be involved in project teams, holding the primary responsibility to drive the project forward with focus on the Department of Drug Metabolism/Non-Clinical Safety Research area and as part of the project team progress our development projects according to agreed project plans. Furthermore, we expect you to be driving the science within the Group together with your colleagues.

 

We offer

A position with good opportunities for scientific and personal development in a dynamic Department with enthusiastic colleagues.

 

Qualifications

Our preferred candidate

  • Holds a PhD in biochemistry, pharmacy, organic chemistry, chemical engineering or equivalent.
  • Has hands on experience with in vitro DDI methods and LC-MS techniques.
  • Has strong experimental interest and desire to get involved in the daily laboratory work.
  • Has experience within and thorough understanding of enzymology of major drug metabolizing enzymes, inhibition kinetics and design of DDI studies
  • Experience with DDI studies on peptides and oligonucleotides including analysis would be an advantage
  • Experience with PBPK modelling and simulations would be an advantage
  • Has experience with DDI guidelines, as well as GLP studies and preparation of regulatory summary documents (i.e. IB, IND, CTD)
  • Has an analytical mindset and focus on delivering high quality data in due time
  • Is enthusiastic, ambitious, proactive and a true team player
  • Has good communication skills and is fluent in English.

 

Further information

For further information please contact Director Mette G. Hvenegaard at +45 3083 3174. We also recommend that you have a look at our website www.lundbeck.com.

 

Your application

Please click on the link below to apply for the job. Applications must be received no later than October 4th 2020.

 

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.


An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18.1 billion in 2018 (EUR 2.4 billion; USD 2.8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.